



Original Investigation

Use of benzodiazepines and antidepressants in patients who attend a Rheumatology clinic



Antonio Álvarez-Cienfuegos^{a,*}, María Paz Martínez-Vidal^b, José Raúl Noguera-Pons^c, Vega Jovani^d, Raquel Martín-Domenech^e, María Teresa Pedraz-Penalva^e, Pilar Bernabeu-Gonzálvez^d

^a Rheumatology Section, Hospital Vega-Baja, Orihuela, Spain

^b Rheumatology Section, Hospital Universitario San Juan de Alicante, Alicante, Spain

^c Rheumatology Section, Hospital General Universitario de Elche, Elche, Spain

^d Rheumatology Section, Hospital General Universitario de Alicante, Alicante, Spain

^e Rheumatology Section, Hospital General Universitario de Elda, Elda, Spain

ARTICLE INFO

Article history:

Received 22 June 2020

Accepted 7 October 2020

Available online 1 February 2021

Keywords:

Antidepressants
Benzodiazepines
Rheumatology
Prevalence

ABSTRACT

Introduction: During the last decades, benzodiazepines (BZD) and antidepressants (ADP) have been among the most prescribed therapies in all developed countries. They have side effects, and BZD carry a risk of abuse and dependence disorders. The purpose of this study was to evaluate the prevalence of BZD and ADP among patients who attend a Rheumatology clinic, as well as the indication for these drugs.

Methods: The study included patients who were referred for the first time to the Rheumatology clinic. Demographical data, reason for referral, and final diagnosis were recorded. The indication for ADP and/or BZD was recorded, as well as the duration of treatment. Sample size was estimated for a 0.05% alpha risk. Univariate and multivariate analyses were performed in order to study the relationships with the demographical or clinical characteristics. **Results:** A total of 350 patients were included (women 77.1%, men 22.9%). Most of them (73.4%) had been referred for musculoskeletal pain. More than a third (36.6%) of patients were on BZD and/or ADP. The most frequent reasons for their prescription were anxiety, depression, and insomnia. The final diagnosis in the clinic was a non-inflammatory condition in 82%, and an inflammatory one in 18%. In the univariate analyses, the use of BZD/ADP was associated with female gender ($p < .001$), unemployment ($p < .001$) and non-inflammatory final diagnosis ($p < .001$). In the multivariate analyses, the use of BZD and/or ADP was associated with female sex ($p = .002$ [OR 3.4, 95% CI; 1.6–7.4]), and a non-inflammatory final diagnosis, specifically fibromyalgia ($p = .007$ [OR 16.1, 95% CI; 2.2–120.7]).

Conclusion: Use of BZD and ADP is high and associated with non-inflammatory disease.

© 2020 Asociación Colombiana de Reumatología. Published by Elsevier España, S.L.U. All rights reserved.

* Corresponding author.

E-mail address: antonioalvarezdc@gmail.com (A. Álvarez-Cienfuegos).

<https://doi.org/10.1016/j.rcreu.2020.10.006>

0121-8123/© 2020 Asociación Colombiana de Reumatología. Published by Elsevier España, S.L.U. All rights reserved.

Prevalencia de consumo de benzodiacepinas y antidepresivos en los pacientes que acuden por primera vez a la consulta de reumatología

R E S U M E N

Palabras clave:
Antidepresivos
Benzodiacepinas
Reumatología
Prevalencia

Introducción: Durante las últimas décadas, las benzodiacepinas (BZD) y los antidepresivos (ADP) han estado entre las terapias más prescritas en todos los países desarrollados. Estos fármacos tienen efectos secundarios y las BZD pueden ocasionar abuso y problemas de dependencia. El objetivo de este estudio fue evaluar la prevalencia de consumo de BZD y ADP entre los pacientes que acuden a una consulta de reumatología por primera vez, así como la indicación para ellos.

Métodos: Se incluyeron pacientes remitidos por primera vez a la consulta de reumatología. Se registraron los datos demográficos, el motivo de la derivación y el diagnóstico final. Con respecto al tratamiento con ADP y/o BZD, se registraron su duración y la indicación de la prescripción. El tamaño de la muestra se estimó para un riesgo alfa de 0,05%. Se realizaron análisis univariantes y multivariantes para estudiar las asociaciones con características demográficas o clínicas.

Resultados: Se incluyeron 350 pacientes (mujeres 77,1%, hombres 22,9%). La mayoría de ellos habían sido remitidos por dolor musculoesquelético (73,4%). Más de un tercio (36,6%) de los pacientes estaban en tratamiento con BZD y/o ADP. Las causas más frecuentes para su prescripción fueron ansiedad, depresión e insomnio. El diagnóstico final fue patología no inflamatoria en el 82% de los casos e inflamatoria en el 18% de estos. En el análisis univariante, el uso de BZD y/o ADP se asoció con el sexo femenino ($p < 0,001$), el desempleo ($p < 0,001$) y el diagnóstico de patología no inflamatoria ($p < 0,001$). En el análisis multivariante, el uso de BZD y/o ADP se asoció con el sexo femenino ($p = 0,002$ [OR 3,4; IC 95% 1,6-7,4]) y el diagnóstico de patología no inflamatoria, específicamente con la fibromialgia ($p = 0,007$ [OR 16,1; IC 95% 2,2-120,7]).

Conclusión: El consumo de BZD y ADP es frecuente y está asociado con patología no inflamatoria.

© 2020 Asociación Colombiana de Reumatología. Publicado por Elsevier España, S.L.U. Todos los derechos reservados.

Introduction

Benzodiazepines (BZD) are a group of psychotropic drugs with mainly anxiolytic effect. Their mechanism of action is based on their indirect gamma-aminobutyric acid (GABA) agonist effect. Nowadays they are one of the most prescribed groups of drugs in medical practice.^{1,2} According to a study carried out in 2004,³ the use of anxiolytics and hypnotics in Spain experienced a growth of 56% from 1995 to 2002, with an average annual increase of 2.78 DDD (Defined Daily Dose) per 100 inhabitants per day.

On the other hand, antidepressants (ADP)⁴ are the drugs to treat the symptoms of depression. There are four main types: SSRIs (Selective Serotonin Reuptake Inhibitors); IRSNs (Selective Serotonin and Norepinephrine Reuptake Inhibitors); Tricyclic; MAOIs (Monoamine oxidase inhibitors). ADPs can be used to treat other conditions such as: moderate to severe depression (also mild depression depending on individual profiles), severe anxiety and panic attacks, obsessive compulsive disorder; chronic pain; eating disorders and post-traumatic stress disorder. The use of ADP⁵ has tripled in Spain between 2000 and 2013, going from 26.5 to 79.5 doses per 1000 inhabitants.

Our objective was to evaluate the prevalence of BDZ and/or ADP use among those patients who were referred for the first time to a Rheumatology consult for evaluation, as well as the indication. We also aimed to study the association of these drugs to any clinical or sociodemographic characteristic of the patients.

Materials and methods

Patients

Descriptive cross-sectional study carried out in five hospitals in the province of Alicante (Southeast of Spain). Patients referred for the first time to the Rheumatology clinic were consecutively included between January 1 and April 1, 2019. The inclusion criteria were age (adults over 18 years old) and acceptance to participate by signing the informed consent.

All the data were collected at this first visit. Sociodemographic data included: age, job situation (active, unemployed, student, retired, and pensioner/disabled) and partner/marital status (single, married/partner, widow, divorced). Clinical data included: the initial clinical suspicion for referral to Rheumatology; the specialist referring; the use of ADP and/or BZD,

its indication (pain, anxiety, depression, insomnia, others), duration and prescriber; and the final diagnosis according to the Rheumatologist (inflammatory/autoimmune condition; fibromyalgia; bone disorder-like osteoporosis or Paget's disease-; and other non-inflammatory conditions such as osteoarthritis or soft tissue disorders).

The study was approved by the ethical committee for scientific research of the Hospital General Universitario de Elche with the code AAC-BZD-2018-01 and was carried out following the precepts of the Declaration of Helsinki.

Statistical study

Assuming an alpha risk of 0.05%, a sample size of 350 patients was calculated. A descriptive statistical analysis was performed in which the quantitative variables are presented as means and standard deviations and the qualitative ones as frequencies and percentages. The independent variable was the use of BZD and/or ADT; its association with socio-demographic variables and clinical variables was studied, first by simple logistic regression, establishing the significance level at $p < 0.05$. Then, ANOVA multivariate analysis was performed and the odds ratio (OR) calculated, for which a 95% confidence interval (CI) was estimated. Secondly, the same association study was carried out for the use of BZD and ADT separately. For the association study, two models were used. First, with any of the individual dependent variables described. Second, reclassifying the employment situation and the final diagnosis. The employment situation was reclassified into "active" and "not active" (retired, unemployed, pensioner/disabled). The final diagnosis was reclassified into "inflammatory" and "non-inflammatory" (bone disorders, fibromyalgia, osteoarthritis, soft tissue disorders and others). The data were analysed using the statistical program "SPSS", version 25 (IBM).

Results

Descriptive study

We included 350 patients, 270 women and 80 men, with a mean age of 58 years old. Concerning job status, 40% had active work and 31.4% were unemployed. 250 patients were married or lived as a couple (71.4%). The main reason for referral to the Rheumatology clinic was the presence of musculoskeletal pain (73.4%), others (26.6%) causes of consultation were a compendium of less frequent complaints including: loss of strength, asthenia, inflammation, Raynaud's phenomenon, constitutional syndrome and also osteoporosis. A total of 128 patients (36.6%) were on BZD and/or ADP treatment at the time of the visit: 107 patients were taking BZD (30.6%), 68 ADP (19.4%), and 47 (13.4%) both treatments. The most frequent reasons for BZD and/or ADP prescription were anxiety (31.2%), depression (28.9%) and insomnia (27.4%), with much less frequent indication for musculoskeletal pain (12.5%). Most of the BZD and/or ADP prescriptions had been made by the family doctor (68%). The final diagnosis according to the Rheumatologist were: inflammatory/autoimmune conditions 18%; bone disorders 14.6%; fibromyalgia 11.4%; others

Table 1 – Characteristics of the study subjects.

Age, years (mean $\pm$ SD)	58 $\pm$ 14
Gender, n 350	
Female, n (%)	270 (77.14)
Male, n (%)	80 (22.9)
Employment status, n 350	
Student, n (%)	1 (0.3)
Active work, n (%)	140 (40)
Unemployed, n (%)	110 (31.4)
Disabled, n (%)	11 (3.1)
Retired, n (%)	88 (25.1)
Marital status, n 350	
Married, n (%)	250 (71.4)
Single, n (%)	35 (10)
Widowed, n (%)	32 (9.1)
Divorced, n (%)	33 (9.4)
Reason for consultation, n 350	
Pain, n (%)	257 (73.4)
Others, n (%)	93 (26.6)
BZD consumption, n 350	
Yes, n (%)	107 (30.6)
No, n (%)	243 (69.4)
ADP consumption, n 350	
Yes, n (%)	68 (19.4)
No, n (%)	282 (80.6)
BZD and ADP consumption, n 350	
Yes, n (%)	47 (13.4)
No, n (%)	303 (86.6)
Reasons for BZD and/or ADP prescription, n 128	
Pain, n (%)	16 (12.5)
Anxiety, n (%)	40 (31.2)
Depression, n (%)	37 (28.9)
Insomnia, n (%)	35 (27.4)
Rheumatologic diagnosis, n 350	
Inflammatory/autoimmune conditions, n (%)	63 (18)
Bone disorders, n (%)	52 (14.6)
Fibromyalgia, n (%)	40 (11.4)
Others, n (%)	195 (56)
SD: standard deviation, BZD: Benzodiazepines, ADP: antidepressants.	

(like soft tissue disorders or osteoarthritis) 56%. Results are shown in [Tables 1 and 2](#).

Association study

Use of BDZ and/or ADP

In the univariate analysis the use of BZD and/or ADP was associated with female sex ($p < 0.001$), employment status "disabled" ($p < 0.001$) and final diagnosis "non-inflammatory" ($p < 0.001$). Results are shown in [Table 3](#). In the multivariate analysis ([Table 4](#)), the association with female sex was confirmed [$p = 0.002$; OR 3.4 (95% CI 1.6–7.4)] and an association was found with the final diagnosis of fibromyalgia [$p = 0.007$; OR 16.1 (95% CI 2.2–120.7)] ([Table 4](#)). No association was found between the consumption of psychotropic drugs and age.

Table 2 – Consumption of BZD and/or ADP according with the Rheumatologic diagnosis.

BZD consumption, n 107	
Inflammatory/autoimmune conditions, n (%)	14 (13.1)
Bone disorders, n (%)	15 (14)
Fibromyalgia, n (%)	27 (25.2)
Others, n (%)	51 (47.7)
ADP consumption, n 68	
Inflammatory/autoimmune conditions, n (%)	7 (10.3)
Bone disorders, n (%)	8 (11.8)
Fibromyalgia, n (%)	24 (35.3)
Others, n (%)	29 (42.6)
BZD and ADP consumption, n 47	
Inflammatory/autoimmune conditions, n (%)	3 (6.4)
Bone disorders, n (%)	5 (10.6)
Fibromyalgia, n (%)	19 (40.4)
Others, n (%)	20 (42.6)

BZD: Benzodiazepines, ADP: antidepressants.

Table 3 – Univariate analysis.

	p-Value
BZD and/or ADP	
Sex (female)	<0.001
Employment status (disabled)	<0.001
Rheumatologic diagnosis (non-inflammatory)	<0.001
BZD	
Sex (female)	0.001
Employment status (Unemployed)	<0.001
Rheumatologic diagnosis (non-inflammatory)	<0.001
Age	<0.001
ADP	<0.001
ADP	
Sex (female)	<0.001
Employment status (Unemployed)	0.001
Rheumatologic diagnosis (non-inflammatory)	<0.001
BZD	<0.001

BZD: Benzodiazepines, ADP: antidepressants.

Table 4 – Multivariate analysis.

	OR (95% CI)	p-Value
BZD and/or ADP		
Sex (female)	3.4 (1.6–7.4)	0.002
Fibromyalgia	16.1 (2.2–120.7)	0.007
BZD		
Sex (female)	2.5 (1.1–5.3)	0.020
Fibromyalgia	22.2 (1.9–261.9)	0.014
ADP		
Sex (female)	8.3 (1.9–36.4)	0.005

OR: Odds Ratio, BZD: Benzodiazepines, ADP: antidepressants.

Use of BZD alone

In the univariate analysis, the use of BZD was associated with older age ($p < 0.001$), female sex ($p = 0.001$), employment status “not active” ($p < 0.001$), the use of ADT ($p < 0.001$) and at the final “non-inflammatory” diagnosis ($p < 0.001$) (Table 3). In the multivariate analysis, only association with female sex was found

[$p = 0.02$; OR 2.5 (95% CI 1.1–5.3)] and fibromyalgia diagnosis [$p = 0.014$; OR 22.2 (95% CI 1.9–261.9)] (Table 4).

Use of ADP alone

In the univariate analysis, the use of ADT was associated with female sex ($p < 0.001$), “not active” employment status ($p = 0.001$), BDZ use ($p < 0.001$) and final “non-inflammatory” diagnosis ($p < 0.001$) (Table 3). In the multivariate analysis, only association with female sex was found [$p = 0.005$ (OR 8.3, 95% CI 1.9–36.4)] (Table 4).

Any treatment, alone or combined, was associated with the civil status.

Discussion

Our results show that more than a third of the patients who come to the Rheumatology clinic for the first time were on BZD and/or ADP. The BZD prescription among these patients was higher than that observed in the Spanish general population (30.6% vs 18.7%).⁶ Similarly, the ADP prescription was also higher comparing with the general population (19.4% vs 8.5%).⁷ They had been both prescribed mostly by de general practitioner, and musculoskeletal pain accounted for a small part of the indications.

The use of psychotropic drugs was in all our analyses consistent and associated with the female sex and the diagnosis of non-inflammatory conditions. The use of BZD was also associated with older age in the univariate study, which has already been reported in other international works.^{8,9} The use of BZD was shown to increase from 2.6% at 18–35 years old, to 8.7% at 65–80 years old in the American population.⁸ In a systematic review, prolonged use of BZD was also associated with older patient age.¹⁰ We also found an association with the “not active” employment situation. In an Italian population survey, unemployment was associated with a higher consumption of BZD.¹¹ In a series of German patients, clear association between unemployment and a longer use of BZD was found.¹² On the other hand, in our series, patients who consumed BZD had also higher probability of using ADP in the univariate study. Previous studies have already described an association between ADP consumption and increased use of BZD.^{13,14} However, in our series, the use of BZD was not associated with unemployment, age, or ADP consumption in the multivariate analyses. This could be explained by an insufficient sample size. We only found association with the female sex and with the diagnosis of non-inflammatory pathology. The higher prevalence of BZD consumption in the female sex has been corroborated in other studies,^{15,16} as well as the association with non-inflammatory pathology, especially with fibromyalgia, an entity characterized by the presence of pain.

Concerning the use of ADP in our patients, in the univariate analysis we observed association with age, unemployment, consumption of BZD and with the diagnosis of fibromyalgia. Other studies¹⁷ have also communicated an increased use of ADP in older people. However, in the multivariate analysis, we found only an association with female sex, which has also been described in previous works.¹⁸ On the other hand, ADPs may be helpful as adjuvant therapy to the treatment of different rheumatic conditions, mainly those with

chronic pain, because they enhance the effect of opioids or non-steroidal anti-inflammatory drugs.¹⁹ They can be used in chronic severe rheumatic conditions with sequelae, but overall in fibromyalgia.²⁰ Among them, duloxetine and amitriptyline are the most frequently recommended antidepressants. Prevalence of musculoskeletal pain varies with age and sex. It has been communicated that neck, shoulders, knees and back pain are 1.5 times more common in women, while fibromyalgia is up to 4 times more frequent in women.²¹ In our study, more than two thirds were women, which may have influenced the association results by a selection bias.

Nevertheless, it is remarkable that in our series of patients who attend a Rheumatology consult for the first time, the use of psychotropic drugs is frequent; it is mostly prescribed in the primary care setting for psychiatric needs over all and these patients are finally diagnosed with non-inflammatory conditions. That is to say, patients on psychotropic drugs who attend a Rheumatology consult are more probably being finally diagnosed with a non-inflammatory condition. Nevertheless, we need to remember that most of the patients were referred to Rheumatology because of pain which may be a frequent symptom in conditions such as depression²² or anxiety. The main limitation of this study is its cross-sectional design, so we cannot make conclusions about the definite association between the use of BZD and/or ADP and a final Rheumatology diagnosis.

In conclusion, the use of BZD and ADP is frequent among the patients who attend a Rheumatology consult for the first time, and they are associated to a final non-inflammatory condition diagnosis.

Conflicts of interest

The authors declare that they have no conflict of interest.

REFERENCES

1. Fassaert T, Dorn T, Spreeuwenberg PM, van Dongen MCJM, van Gool CJAW, Yzermans CJ. Prescription of benzodiazepines in general practice in the context of a man-made disaster: a longitudinal study. *Eur J Public Health*. 2007;17:612–7, <http://dx.doi.org/10.1093/eurpub/ckm020>.
2. Rogers A, Pilgrim D, Brennan S, Sulaiman I, Watson G, Chew-Graham C. Prescribing benzodiazepines in general practice: a new view of an old problem. *Health (London)*. 2007;11:181–98, <http://dx.doi.org/10.1177/1363459307074693>.
3. García del Pozo J, de Abajo Iglesias FJ, Carvajal García-Pando A, Montero Corominas D, Madurga Sanz M, García del Pozo V. The use of anxiolytic and hypnotic drugs in Spain (1995–2002). *Rev Esp Salud Publica*. 2004;78:379–87, <http://dx.doi.org/10.1590/s1135-57272004000300007>. Spanish.
4. Bourin M, David DJ, Jolliet P, Gardier A. Mechanism of action of antidepressants and therapeutic perspectives. *Therapie*. 2002;57:385–96. French.
5. Agencia Española de Medicamentos y Productos Sanitarios. Utilización de medicamentos antidepresivos en España durante el periodo 2000–2013. Informe de Utilización de Medicamentos U/AD/V1/14012015 [Internet]; 2015. Available from: <http://www.aemps.gob.es/medicamentosUsoHumano/observatorio/docs/antidepresivos-2000-2013.pdf> [consulted 14.01.15].
6. Agencia Española de Medicamentos y Productos Sanitarios. Utilización de medicamentos ansiolíticos e hipnóticos en España durante el periodo 2000–2012. Informe de utilización de medicamentos U/HAY/V1/17012014 [Internet]; 2017. Available from: http://www.aemps.gob.es/medicamentosUsoHumano/observatorio/docs/ansioliticos_hipnoticos-2000-2012.pdf [consulted 27.01.14].
7. Serna C, Cruz I, Galván L, Real J, Gascó E, Soler-González J. Evolution of the prevalence and incidence of consumption of antidepressants in a Spanish region (2002–2007). *Ment Health Fam Med*. 2010;7:9–15.
8. Olfson M, King M, Schoenbaum M. Benzodiazepine use in the United States. *JAMA Psychiatry*. 2015;72:136–42, <http://dx.doi.org/10.1001/jamapsychiatry.2014.1763>.
9. Steinman MA, Low M, Balicer RD, Shadmi E. Epidemic use of benzodiazepines among older adults in Israel: epidemiology and leverage points for improvement. *J Gen Intern Med*. 2017;32:891–9, <http://dx.doi.org/10.1007/s11606-017-4059-1>.
10. Kurko TA, Saastamoinen LK, Tähkäpää S, Tuulio-Henriksson A, Taiminen T, Tiihonen J, et al. Long-term use of benzodiazepines: definitions, prevalence and usage patterns – a systematic review of register-based studies. *Eur Psychiatry*. 2015;30:1037–47, <http://dx.doi.org/10.1016/j.eurpsy.2015.09.003>.
11. Magrini N, Vaccheri A, Parma E, D'Alessandro R, Bottoni A, Occhionero M, et al. Use of benzodiazepines in the Italian general population: prevalence, pattern of use and risk factors for use. *Eur J Clin Pharmacol*. 1996;50:19–25, <http://dx.doi.org/10.1007/s002280050063>.
12. Mokhar A, Tillenburg N, Dirmaier J, Kuhn S, Härter M, Verthein U. Potentially inappropriate use of benzodiazepines and z-drugs in the older population-analysis of associations between long-term use and patient-related factors. *PeerJ*. 2018;6:e4614, <http://dx.doi.org/10.7717/peerj.4614>.
13. Olfson M, Pincus HA. Use of benzodiazepines in the community. *Arch Intern Med*. 1994;154:1235–40.
14. Simpson RJ, Power KG, Wallace LA, Butcher MH, Swanson V, Simpson EC. Controlled comparison of the characteristics of long-term benzodiazepine users in general practice. *Br J Gen Pract*. 1990;40:22–6.
15. Kokkevi A, Fotiou A, Arapaki A, Richardson C. Prevalence, patterns, and correlates of tranquilizer and sedative use among European adolescents. *J Adolesc Health*. 2008;43:584–92, <http://dx.doi.org/10.1016/j.jadohealth.2008.05.001>.
16. Galduroz JC, Noto AR, Nappo SA, Carlini EA. Household survey on drug abuse in Brazil: study involving the 107 major cities of the country—2001. *Addict Behav*. 2005;30:545–56, <http://dx.doi.org/10.1016/j.addbeh.2004.08.004>.
17. Gómez-Lumbreras A, Ferrer P, Ballarín E, Sabaté M, Vidal X, Andretta M, et al. Study of antidepressant use in 5 European settings. Could economic, sociodemographic and cultural determinants be related to their use? *J Affect Disord*. 2019;249:278–85, <http://dx.doi.org/10.1016/j.jad.2019.01.039>.
18. Olié JP, Elomari F, Spadone C, Lépine JP. Antidepressants consumption in the global population in France. *Encephale*. 2002;28:411–7. French.
19. Jané F, Baños JE. Psicofármacos en el tratamiento del dolor. In: Aliaga L, Baños JE, de Barutell C, Molet J, Rodríguez de la Serna A, editors. *Tratamiento del dolor, teoría y práctica*. Barcelona: MCR; 1995. p. 99–112.
20. Macfarlane GJ, Kronisch C, Dean LE, Atzeni F, Häuser W, Fluß E, et al. EULAR revised recommendations for the management of fibromyalgia. *Ann Rheum Dis*. 2017;76:318–28, <http://dx.doi.org/10.1136/annrheumdis-2016-209724>.
21. LeResche L. Epidemiologic perspectives on sex differences in pain. In: Fillim RB, editor. *Sex, gender, and pain*. Progress

-
- in pain research and management, vol. 17. Seattle: IASP Press; 2000. p. 233-49.
22. Kobayashi-Gutiérrez A, Martínez-Bonilla G, Bernard-Medina AG, Troyo-Sanroman R, González-Díaz V, Castro-Contreras E, et al. Depression and its correlation with in patients pain in the rheumatology service of a Mexican teaching hospital. Rheumatol Int. 2009;29:1169-75, <http://dx.doi.org/10.1007/s00296-008-0834-y>.